Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;65(7):588-592.
doi: 10.1111/ajd.14335. Epub 2024 Jun 18.

JAK inhibitors in refractory dermatomyositis: A case series

L Corbella-Bagot  1 , X Bosch-Amate  1 , E Gimeno-Ribes  1 , J Gil-Lianes  1 , P Giavedoni  1 , J C Milisenda  2   3 , S Prieto-González  4   5 , R Hurtado García  6 , J M Mascaró Jr  1
Affiliations

JAK inhibitors in refractory dermatomyositis: A case series

L Corbella-Bagot et al. Australas J Dermatol. 2024 Nov.

Abstract

This retrospective cohort study assessed the efficacy and safety of Janus kinase (JAK) inhibitors, tofacitinib and baricitinib, in 14 patients with refractory dermatomyositis (DM), a multisystemic autoimmune disorder with limited therapeutic options. Results demonstrated a significant median decrease of 21 points and a 76% reduction in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores, along with a complete resolution of muscular symptoms in 64% of the patients. JAK inhibitors were effective in managing refractory DM across various subtypes with mild and manageable adverse events.

Keywords: JAK inhibitors; baricitinib; dermatomyositis; juvenile; refractory; tofacitinib.

PubMed Disclaimer

References

REFERENCES

    1. Callen JP. Dermatomyositis. Lancet. 2000;355(9197):53–57. https://doi.org/10.1016/S0140‐6736(99)05157‐0
    1. Paik JJ, Lubin G, Gromatzky A, Mudd PN, Ponda MP, Christopher‐Stine L. Use of JAK inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 2023;41(2):348–358. https://doi.org/10.55563/clinexprheumatol/hxin6o
    1. Zhao Q, Zhu Z, Fu Q, Shih Y, Wu D, Chen L, et al. Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open‐label study. J Am Acad Dermatol. 2022;87(6):1374–1376. https://doi.org/10.1016/j.jaad.2022.08.025
    1. Huang B, Wang X, Niu Y, Ding Y, Wang X, Tan Q, et al. Long‐term follow‐up of Janus‐kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis. Rheumatology (Oxford). 2023;62(3):1227–1237. https://doi.org/10.1093/rheumatology/keac399
    1. Paik JJ, Casciola‐Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, et al. Study of tofacitinib in refractory dermatomyositis: an open‐label pilot study of ten patients. Arthritis Rheumatol. 2021;73(5):858–865. https://doi.org/10.1002/art.41602

LinkOut - more resources